Best for
Mobile

DaVita Inc (DVA) is a leading medical care facilities business based in the US. DaVita is listed on the NYSE and employs 65,000 staff. All prices are listed in US Dollars.
Best for
Mobile
Best for
Low-cost
Best for
All rounder
Best for
Beginners
52-week range | $62.2 - $125.28 |
---|---|
50-day moving average | $116.3934 |
200-day moving average | $96.7012 |
Wall St. target price | $119.33 |
PE ratio | 17.9054 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $6.679 |
Other fees may apply. Your capital is at risk.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing DaVita stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of DaVita's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
DaVita's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, DaVita shares trade at around 18x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
DaVita's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.9811. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into DaVita's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
DaVita's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $2.4 billion.
The EBITDA is a measure of a DaVita's overall financial performance and is widely used to measure a its profitability.
Revenue TTM | $11.5 billion |
---|---|
Operating margin TTM | 15.57% |
Gross profit TTM | $3.5 billion |
Return on assets TTM | 6.51% |
Return on equity TTM | 30.61% |
Profit margin | 7.32% |
Book value | $13.84 |
Market capitalisation | $13.4 billion |
TTM: trailing 12 months
There are currently 4.0 million DaVita shares held short by investors – that's known as DaVita's "short interest". This figure is 9.4% down from 4.4 million last month.
There are a few different ways that this level of interest in shorting DaVita shares can be evaluated.
DaVita's "short interest ratio" (SIR) is the quantity of DaVita shares currently shorted divided by the average quantity of DaVita shares traded daily (recently around 718698.00724638). DaVita's SIR currently stands at 5.52. In other words for every 100,000 DaVita shares traded daily on the market, roughly 5520 shares are currently held short.
However DaVita's short interest can also be evaluated against the total number of DaVita shares, or, against the total number of tradable DaVita shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case DaVita's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 DaVita shares in existence, roughly 40 shares are currently held short) or 0.0545% of the tradable shares (for every 100,000 tradable DaVita shares, roughly 55 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against DaVita.
Find out more about how you can short DaVita stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like DaVita.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 20.07
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and DaVita's overall score of 20.07 (as at 01/01/2019) is pretty good – landing it in it in the 24th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like DaVita is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 2.6/100
DaVita's environmental score of 2.6 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that DaVita is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 10.68/100
DaVita's social score of 10.68 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that DaVita is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 7.8/100
DaVita's governance score puts it squarely in the 3rd percentile of companies rated in the same sector. That could suggest that DaVita is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, DaVita scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that DaVita has, for the most part, managed to keep its nose clean.
DaVita Inc was last rated for ESG on: 2019-01-01.
Total ESG score | 20.07 |
---|---|
Total ESG percentile | 24.1 |
Environmental score | 2.6 |
Environmental score percentile | 3 |
Social score | 10.68 |
Social score percentile | 3 |
Governance score | 7.8 |
Governance score percentile | 3 |
Level of controversy | 2 |
We're not expecting DaVita to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
DaVita's shares were split on a 2:1 basis on 9 September 2013. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your DaVita shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for DaVita shares which in turn could have impacted DaVita's share price.
Over the last 12 months, DaVita's shares have ranged in value from as little as $62.2 up to $125.28. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while DaVita's is 1.3072. This would suggest that DaVita's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Subscribe to trending stock alerts for a chance to win
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2019, it provided dialysis and administrative services in the United States through a network of 2,753 outpatient dialysis centers serving approximately 206,900 patients; and operated 259 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 28,700 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was founded in 1994 and is headquartered in Denver, Colorado.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.